{"hands_on_practices": [{"introduction": "The effectiveness of any vaccine hinges on its ability to trigger the correct arm of the adaptive immune system. Viral vector vaccines are powerful tools precisely because they can mimic a natural viral infection within our cells, allowing for the presentation of antigens through specific intracellular pathways. This first exercise challenges you to apply your knowledge of antigen processing to predict the primary immune response generated by a vector that produces a viral protein inside a host cell, a core principle in vaccine design [@problem_id:2284998].", "problem": "A team of immunologists is developing a novel vaccine against a pathogenic virus. They are using a replication-deficient adenoviral vector, which is engineered to infect host cells and cause them to synthesize a single protein from the target pathogen. The chosen protein is the viral nucleocapsid protein, an internal structural component that is essential for viral replication but is not present on the exterior surface of the mature virus particle. After intramuscular injection in a test subject, the adenoviral vector successfully infects muscle cells, leading to the intracellular production of this nucleocapsid protein.\n\nAssuming the vaccine functions as designed, which of the following outcomes describes the primary and most effective adaptive immune response this vaccine is expected to elicit to combat a future infection by the target pathogen?\n\nA. A high-titer antibody response from plasma cells that can directly bind to and neutralize free-floating virus particles in the bloodstream.\n\nB. A robust cell-mediated response involving cytotoxic T-lymphocytes (CTLs) that can recognize and destroy host cells infected with the virus.\n\nC. A significant increase in the population of memory B-cells that are primed to respond to the viral surface glycoproteins.\n\nD. A rapid local inflammatory response mediated by the complement system cascade a few minutes after infection.\n\nE. The differentiation of T-helper cells primarily into the $T_H2$-subset, which specializes in activating eosinophils and mast cells.", "solution": "The adenoviral vector infects host cells and causes intracellular synthesis of the viral nucleocapsid protein. Because the antigen is produced endogenously within the cytosol of infected host cells, it follows the endogenous antigen processing pathway:\n1. The intracellular nucleocapsid protein is degraded by the proteasome into peptide fragments.\n2. These peptides are transported into the endoplasmic reticulum via TAP.\n3. Peptides are loaded onto MHC class I molecules in the endoplasmic reticulum.\n4. The peptide–MHC class I complexes are presented on the surface of the infected cells to CD8+ T cells.\n5. Naive CD8+ T cells recognizing these peptide–MHC class I complexes become activated (with appropriate costimulation, often provided via cross-priming by professional antigen-presenting cells), proliferate, and differentiate into cytotoxic T-lymphocytes (CTLs) and memory CD8+ T cells.\n\nUpon future infection by the target pathogen, host cells infected by the virus will again present nucleocapsid-derived peptides on MHC class I, allowing memory and effector CTLs to recognize and kill these infected cells via perforin/granzyme and Fas–FasL pathways, thereby limiting viral replication. This is the primary and most effective adaptive response elicited by an intracellularly expressed, non-surface viral antigen.\n\nBy contrast:\n- Neutralizing antibodies (Option A) primarily target exposed surface proteins of virions; an internal nucleocapsid antigen does not enable effective neutralization of free virions.\n- Memory B cells specific for viral surface glycoproteins (Option C) would not be optimally induced because the vaccine encodes only the internal nucleocapsid, not surface glycoproteins.\n- A rapid complement-mediated inflammatory response (Option D) is an innate, immediate response, not the primary adaptive response targeted by such a vaccine.\n- Predominant $T_H2$ differentiation (Option E) is associated with humoral and anti-helminth responses (eosinophils, mast cells), not the cytotoxic antiviral response driven by endogenous antigen presentation.\n\nTherefore, the expected primary and most effective adaptive immune response is a robust cell-mediated CD8+ CTL response that recognizes and eliminates virus-infected cells.", "answer": "$$\\boxed{B}$$", "id": "2284998"}, {"introduction": "A complete immune response is a beautifully coordinated event unfolding across different tissues and over time, from the initial innate alarm to the generation of adaptive memory. Modern \"omics\" technologies, like the CITE-seq method described in this problem, allow immunologists to capture this dynamic process with unprecedented detail. In this exercise, you will step into the role of a research scientist, integrating transcriptomic and protein data to piece together the immunological story of a vaccine's entire mechanism of action [@problem_id:2285007].", "problem": "An immunologist is investigating the response to a novel, non-replicating adenoviral vector vaccine designed to express a model antigen. To create a high-resolution map of the immune events, a multi-omics experiment is performed on a mouse model. Mice are vaccinated intramuscularly, and tissues from both the injection-site muscle and the draining lymph node (dLN) are collected at 24 hours and 7 days post-vaccination. Single-cell suspensions from these tissues are analyzed using Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq), a technique that simultaneously measures the full transcriptome (mRNA levels) and a panel of surface proteins for each individual cell.\n\nThe key findings from the CITE-seq data analysis are summarized as follows:\n\n-   **At 24 hours in the injection-site muscle:** The tissue is heavily infiltrated by innate immune cells, predominantly neutrophils and monocytes. Transcriptomic analysis of the monocytes reveals high expression of genes encoding pro-inflammatory cytokines (e.g., `Il1b`, `Tnf`) and molecules for Major Histocompatibility Complex (MHC) class I and class II antigen presentation pathways.\n\n-   **At 24 hours in the draining lymph node (dLN):** A small but distinct population of migratory dendritic cells (DCs) is identified. These cells exhibit high surface protein levels of CD11c and transcriptomic upregulation of `Ccr7`, a gene encoding a chemokine receptor essential for homing to lymph nodes. A subset of these DCs is confirmed to contain transcripts from the adenoviral vector.\n\n-   **At 7 days in the injection-site muscle:** The cellular composition has shifted. The neutrophil population has significantly decreased, while the tissue now contains a mix of macrophages, showing a transcriptomic signature consistent with both inflammation and tissue repair, alongside a small population of tissue-resident T cells.\n\n-   **At 7 days in the draining lymph node (dLN):** A substantial expansion of T cells is observed. Integrated analysis using an antigen-specific tetramer reagent in the CITE-seq panel identifies a robust population of antigen-specific CD8+ T cells. These cells show high transcript levels for `Gzmb` (Granzyme B) and `Ifng` (Interferon-gamma) and high surface protein expression of the activation marker CD44. Concurrently, a population of T follicular helper (Tfh) cells is identified by its characteristic expression of the CXCR5 surface protein and the `Bcl6` transcription factor. This coincides with the appearance of early germinal center B cells.\n\nBased on the integrated analysis of these spatiotemporal multi-omics data, which of the following statements provides the most complete and accurate immunological conclusion regarding the vaccine's mechanism of action?\n\nA. The adenoviral vector directly infects T cells within the draining lymph node, leading to their rapid activation and differentiation into cytotoxic lymphocytes and T follicular helper cells by day 7.\n\nB. The primary immune response to the vaccine is localized entirely within the injection-site muscle, where a sustained inflammatory environment is solely responsible for generating long-term adaptive immunity.\n\nC. The intense neutrophil and monocyte infiltration at the injection site at 24 hours is directly responsible for priming the antigen-specific T cell response in the draining lymph node.\n\nD. The vaccine induces a rapid, localized innate inflammatory response in the muscle, which facilitates the migration of antigen-carrying dendritic cells to the draining lymph node to prime a potent, antigen-specific adaptive T and B cell response evident by day 7.\n\nE. The presence of T follicular helper cells and germinal center B cells by day 7 confirms the establishment of sterile, protective immunity against the pathogen from which the antigen was derived.", "solution": "We begin by aligning each experimental observation with established immunological principles to infer the vaccine’s mechanism.\n\nAt 24 hours in the injection-site muscle, there is heavy infiltration by neutrophils and monocytes, with monocytes expressing pro-inflammatory cytokine genes such as `Il1b` and `Tnf` and upregulation of genes involved in MHC class I and class II pathways. Principle: local innate sensing of a vaccine vector induces an acute inflammatory response, primarily recruiting and activating neutrophils and monocytes. The cytokines and chemokines produced shape the local environment and promote activation and maturation of antigen-presenting cells (APCs). Although monocytes can upregulate antigen presentation machinery, the canonical priming of naive T cells occurs in secondary lymphoid organs by professional dendritic cells.\n\nAt 24 hours in the draining lymph node (dLN), a distinct population of migratory dendritic cells (DCs) is identified, with high CD11c and upregulation of `Ccr7`. Principle: `Ccr7` expression enables migration of DCs from peripheral tissues to dLNs along gradients of `Ccl19` and `Ccl21`, positioning them in T cell zones to prime naive T cells. The presence of adenoviral vector transcripts within a subset of these DCs indicates that these DCs have acquired antigen from the vaccine (through direct infection or uptake of antigen), enabling antigen processing and presentation. DCs can present antigen on MHC class I (including via cross-presentation) to CD8 T cells and on MHC class II to CD4 T cells, initiating adaptive responses.\n\nAt 7 days in the injection-site muscle, neutrophil numbers decline and macrophages show a mixed inflammatory and tissue repair transcriptomic signature, with a small population of tissue-resident T cells present. Principle: resolution of acute inflammation with macrophage-driven repair indicates that the primary effector T cell priming has occurred elsewhere, with only modest local T cell presence, which is consistent with effector recruitment or the beginnings of resident memory formation rather than being the site of initial priming.\n\nAt 7 days in the dLN, there is substantial expansion of T cells, including antigen-specific CD8 T cells identified by tetramer, with high `Gzmb` and `Ifng` transcripts and high CD44, indicating activation and cytotoxic differentiation. Principle: robust expansion of antigen-specific CD8 T cells with cytotoxic effector gene expression is the hallmark of successful priming by professional APCs, typically DCs in the LN, following antigen transport from the periphery. Concurrent identification of T follicular helper (Tfh) cells characterized by CXCR5 and `Bcl6`, coincident with early germinal center B cells, indicates that CD4 T cell differentiation into Tfh has occurred and is supporting B cell activation and germinal center initiation, a T cell–dependent humoral response.\n\nNow, we evaluate the options:\n\nA asserts direct infection of T cells in the dLN by the adenoviral vector as the mechanism of activation. The data show vector transcripts in migratory DCs, not in T cells, and the vector is non-replicating. T cell activation classically results from DC-mediated antigen presentation, not direct T cell infection. Therefore, A is not supported.\n\nB claims the response is entirely localized to the muscle and that sustained local inflammation alone generates long-term adaptive immunity. This is contradicted by the clear evidence of robust, antigen-specific T and B cell responses in the dLN by day 7, indicating central priming in the lymph node. Therefore, B is incorrect.\n\nC states that neutrophils and monocytes at the injection site directly prime antigen-specific T cells in the dLN. While they contribute to the inflammatory milieu and can aid antigen availability, the data specifically identify migratory DCs with `Ccr7` upregulation and vector transcripts in the dLN—consistent with DC-mediated priming. Neutrophils and monocytes are not the principal direct primers of naive T cells in the LN. Therefore, C is inaccurate in attributing direct priming to these cells.\n\nD proposes that the vaccine induces rapid, localized innate inflammation in muscle that facilitates migration of antigen-carrying DCs to the dLN, where they prime potent antigen-specific T and B cell responses evident by day 7. This matches all observations: early innate inflammation at the site, `Ccr7`-upregulated migratory DCs containing vaccine transcripts in the dLN at 24 hours, and by day 7 a strong antigen-specific CD8 T cell effector response plus Tfh and early germinal center B cells.\n\nE claims that Tfh and germinal center B cells by day 7 confirm sterile, protective immunity. The presence of early germinal centers and Tfh indicates initiation of humoral responses, but it does not confirm sterile protection; protective efficacy depends on functional antibody quality, quantity, and other immune components, and cannot be concluded solely from these early markers. Therefore, E overinterprets the data.\n\nThus, the most complete and accurate conclusion supported by the integrated data is that early innate inflammation drives DC migration to the dLN, where DCs prime robust antigen-specific T and B cell responses—corresponding to option D.", "answer": "$$\\boxed{D}$$", "id": "2285007"}, {"introduction": "While vaccines are overwhelmingly safe and effective, understanding rare adverse events is a crucial part of immunotoxicology and public health. In this final practice, we shift our focus from a vaccine's intended effects to the pathophysiology of a rare complication, Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT). By applying principles of chemical kinetics, you will model the dynamics of this condition, demonstrating how quantitative reasoning can be used to understand and predict the progression of an immunological pathology [@problem_id:2285018].", "problem": "A rare but serious adverse event following vaccination with certain adenoviral vectors is Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT). The syndrome is initiated when the viral vector forms a complex with a protein called Platelet Factor 4 (PF4), which is released by platelets. These vector-PF4 complexes can trigger an aberrant immune response, leading to the production of pathogenic auto-antibodies. These auto-antibodies then bind to PF4 on the surface of other platelets, causing massive platelet activation and their subsequent removal from circulation, leading to a low platelet count (thrombocytopenia).\n\nConsider a simplified kinetic model for the development of thrombocytopenia in a patient *after* a stable, pathogenic concentration of auto-antibodies, $A_0$, has been established. The concentration of platelets in the blood, $P(t)$, changes over time due to two primary clearance mechanisms:\n1.  A normal, physiological first-order clearance process, characterized by a rate constant $k_N$. The half-life of platelets due to this normal process is $T_{1/2,N}$.\n2.  A pathological, VITT-mediated clearance process. This is modeled as a second-order reaction between the auto-antibodies and the platelets, characterized by a rate constant $k_V$.\n\nThe patient's initial, healthy platelet concentration is $P_0$. Thrombocytopenia is clinically defined as the point when the platelet concentration drops to a critical threshold, $P_{crit}$.\n\nGiven the following parameters:\n-   Initial platelet concentration, $P_0 = 3.20 \\times 10^{11}$ platelets/L\n-   Critical thrombocytopenic concentration, $P_{crit} = 1.20 \\times 10^{11}$ platelets/L\n-   Normal platelet half-life, $T_{1/2,N} = 4.50$ days\n-   Pathogenic auto-antibody concentration, $A_0 = 4.00 \\times 10^{-9}$ M\n-   VITT-mediated clearance rate constant, $k_V = 2.50 \\times 10^{8}$ M$^{-1}$day$^{-1}$\n\nCalculate the time, in days, it takes for the patient's platelet count to fall from $P_0$ to $P_{crit}$. Round your final answer to three significant figures.", "solution": "The platelet concentration $P(t)$ is cleared by two processes:\n- Normal first-order clearance with rate constant $k_{N}$, related to the half-life by the first-order relation $T_{1/2,N}=\\frac{\\ln 2}{k_{N}}$, so $k_{N}=\\frac{\\ln 2}{T_{1/2,N}}$.\n- VITT-mediated clearance modeled as a second-order process with rate $k_{V} A(t) P(t)$. After the pathogenic auto-antibody concentration has stabilized at $A_{0}$, this becomes pseudo-first-order with respect to $P$, with effective rate constant $k_{V}A_{0}$.\n\nThus, the total kinetic equation is\n$$\n\\frac{dP}{dt}=-k_{N}P-k_{V}A_{0}P=-(k_{N}+k_{V}A_{0})P.\n$$\nSeparating variables and integrating from $P_{0}$ at $t=0$ to $P(t)$ at time $t$ gives\n$$\n\\int_{P_{0}}^{P(t)} \\frac{dP}{P}=-(k_{N}+k_{V}A_{0})\\int_{0}^{t} dt,\n$$\nso\n$$\n\\ln\\!\\left(\\frac{P(t)}{P_{0}}\\right)=-(k_{N}+k_{V}A_{0})t,\n$$\nand therefore\n$$\nP(t)=P_{0}\\exp\\!\\big(-(k_{N}+k_{V}A_{0})t\\big).\n$$\nThrombocytopenia occurs when $P(t^{*})=P_{crit}$, yielding\n$$\nt^{*}=\\frac{1}{k_{N}+k_{V}A_{0}}\\,\\ln\\!\\left(\\frac{P_{0}}{P_{crit}}\\right).\n$$\n\nCompute the parameters:\n$$\nk_{N}=\\frac{\\ln 2}{T_{1/2,N}}=\\frac{\\ln 2}{4.50\\ \\text{days}},\n\\quad\nk_{V}A_{0}=(2.50\\times 10^{8}\\ \\text{M}^{-1}\\text{day}^{-1})(4.00\\times 10^{-9}\\ \\text{M})=1.00\\ \\text{day}^{-1}.\n$$\nThus\n$$\nk_{N}+k_{V}A_{0}=\\frac{\\ln 2}{4.50}+1.00\\ \\text{day}^{-1},\n$$\nand\n$$\n\\ln\\!\\left(\\frac{P_{0}}{P_{crit}}\\right)=\\ln\\!\\left(\\frac{3.20\\times 10^{11}}{1.20\\times 10^{11}}\\right)=\\ln\\!\\left(\\frac{8}{3}\\right).\n$$\nNumerically,\n$$\nk_{N}=\\frac{\\ln 2}{4.50}\\approx 0.1540327068\\ \\text{day}^{-1},\\quad\nk_{N}+k_{V}A_{0}\\approx 1.1540327068\\ \\text{day}^{-1},\n$$\n$$\n\\ln\\!\\left(\\frac{8}{3}\\right)\\approx 0.9808292530,\n$$\nso\n$$\nt^{*}\\approx \\frac{0.9808292530}{1.1540327068}\\ \\text{days}\\approx 0.849915\\ \\text{days}.\n$$\nRounded to three significant figures, the time is $0.850$ days.", "answer": "$$\\boxed{0.850}$$", "id": "2285018"}]}